Meredith Sellers Pelster, Associate Program Director of GI Cancer Research at Sarah Cannon Research Institute, Medical Oncologist at SCRI Oncology Partners, shared on LinkedIn:
“A patient I treated on a clinical trial used to bring her young son to Nashville for her study visits. They made a tradition of visiting the zoo together.
When I first met her, a woman only a few years older than me, she had already endured intensive chemotherapy for pancreatic cancer. The treatment was no longer working. She had lost weight and was struggling with nutrition. She was a working professional with a young child and she wanted to know whether there was another option.
She enrolled in a clinical trial of an investigational RAS inhibitor, a medicine designed to target a protein that helps drive many pancreatic cancers. Her cancer came under control for a time. She gained weight and strength. She took her son to Disney World, something she had always hoped to do.
I have never forgotten her, because I saw what meaningful progress could give back to a patient: time, strength, and the ability to be present for moments that mattered to her.
That experience is part of why advances like the recent FDA approval of daraxonrasibresonate so deeply with me. For a disease that has long offered patients few options, each new breakthrough represents a reason for hope.
A new way to treat a familiar driver
For years, we have known that alterations in RAS proteins, particularly KRAS, play a central role in most pancreatic ductal adenocarcinomas, the most common form of pancreatic cancer. Knowing what drives a cancer, however, is different from having a medicine that can effectively target it.
Chemotherapy has long been the backbone of drug treatment for pancreatic cancer, with targeted options available for selected patients. In August 2026, the FDA approved daraxonrasib, the first broadly RAS-targeted medicine for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
In the randomized trial supporting its approval, daraxonrasib improved median overall survival compared with standard chemotherapy among patients whose disease had progressed after one prior line of systemic therapy. In short, more time and more options for this population of patients who have had historically limited treatment options.
That is a significant development for patients who have had too few options. It is also the beginning of a new set of research questions.
Can RAS-directed medicines help more patients if used earlier in treatment? Could combining them with chemotherapy or other targeted therapies improve outcomes? Might they have a role after surgery, when the goal is to reduce the risk of cancer returning? And when a cancer progresses after a RAS-directed treatment, what should come next?
Researchers are exploring these questions. We need evidence from clinical trials before we can know which approaches will help patients. The progress so far gives us a foundation to build on.
Research must reflect what patients need
The patients I meet want more than a promising scientific idea. They want to know whether a treatment is right for their cancer, and whether they can access it when they need it, in their own communities.
That shapes how I think about the trials we prioritize across Sarah Cannon Research Institute and SCRI Oncology Partnerss. We look for studies that address the biology of a patient’s disease and can be carried out in the communities where patients receive care. We also work with our collaborators to remove barriers to enrollment. Timing matters, particularly for someone who has just been diagnosed.
The physicians who see patients close to home are essential to advancing this research. They help identify patients who may be eligible for a study and offer trial opportunities beyond a large referral center. Clinical progress depends on that connection between research and everyday care.
The right path takes a team
New medicines are only one part of the story. Pancreatic cancer can present in very different ways, and the best path for one patient may look quite different from the best path for another.
For a patient whose cancer has not spread but cannot currently be removed with surgery, for example, the questions may involve several specialties. A surgeon, medical oncologist, radiation oncologist, interventional radiologist, and imaging specialist may each see a different part of the picture.
Bringing those perspectives together helps us consider the patient’s options carefully, including whether a clinical trial may be appropriate. As research expands treatment possibilities for patients with both metastatic and locally advanced disease, those conversations become even more valuable.
I was drawn to oncology because I wanted to care for people during one of the most difficult periods of their lives. I was drawn especially to pancreatic cancer because there was so much room to do better.
And there still is. A new approval does not erase the challenges of this disease, and we have much to learn about how to build on this progress. But I think about my patient and the trips she was able to take with her son. I think about the speed with which RAS-directed research has moved from early trials to an approved treatment. And I think about the patients we may be able to help as the next studies answer the questions in front of us.
That is what gives me hope: scientific progress that can create more possibilities for patients and their loved ones.”
Sarah Cannon Research Institute shared this post, adding:
“We often measure progress in cancer research through data. Patients often measure it in milestones, memories and moments.
For Dr. Meredith Sellers Pelster, our Associate Director of Gastrointestinal Cancer Research, the recent FDA approval of a new pancreatic cancer therapy brings to mind a patient who enrolled in a RAS-targeted clinical trial after exhausting standard treatment options. She regained the strength to create meaningful memories with her young son, including a long-awaited trip to Disney World.
Read personal reflections on the recent scientific milestone in pancreatic cancer research and why community-based clinical trials remain essential to expanding options for patients.”
You can also read: Daraxonrasib Receives Positive CHMP Opinion for Previously Treated Metastatic Pancreatic Cancer
